Home » Pharmacyclics Stock Sags on Disappointing Clinical Trial Results

Pharmacyclics Stock Sags on Disappointing Clinical Trial Results

November 6, 2012

Cancer-drug maker Pharmacyclics’ stock dropped almost 20 percent at one point after it released disappointing trial data.
Silicon Valley/San Jose Business Journal

28Sep
The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain
28Sep
Calculating Sample Size to Satisfy FDA Expectations
11Oct
GMP Quality Management vSummit 2023: Where Quality Meets Risk
16Oct
MAGI@home Clinical Research Conference 2023
26Oct
FDA in 2024: What to Expect in an Election Year
08Nov
18th Annual FDA Inspections vSummit

Pharmacyclics Stock Sags on Disappointing Clinical Trial Results

Upcoming Events

The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

Calculating Sample Size to Satisfy FDA Expectations

GMP Quality Management vSummit 2023: Where Quality Meets Risk

MAGI@home Clinical Research Conference 2023

FDA in 2024: What to Expect in an Election Year

18th Annual FDA Inspections vSummit

Featured Products

FDA, FTC and DOJ Enforcement of Medical Device Regulations

Using Real-World Evidence in Drug and Device Submissions

Featured Stories

Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

The Revised ICH E8: A Guide to New Clinical Trial Requirements